Affinity Asset Advisors LLC Decreases Stock Holdings in Savara Inc. $SVRA

Key Points

• Affinity Asset Advisors LLC cut its Savara stake by 10.2% in the first quarter, selling 285,000 shares and ending with 2.51 million shares worth about $13.7 million. It still owned roughly 1.23% of the company.
• Despite that sale, institutional ownership remains very high, with investors holding 87.93% of Savara’s stock. Several other funds recently increased or initiated positions in the biotech company.
• Savara shares fell 4.2% to $5.51, and the company reported a quarterly loss of $0.15 per share, slightly worse than expectations. Analysts currently rate the stock a Moderate Buy with a consensus price target of $10.14.

Affinity Asset Advisors LLC lowered its position in Savara Inc. (NASDAQ:SVRA - Free Report) by 10.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,512,153 shares of the company's stock after selling 285,000 shares during the period. Affinity Asset Advisors LLC owned approximately 1.23% of Savara worth $13,716,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Swedbank AB grew its stake in Savara by 54.5% during the 4th quarter. Swedbank AB now owns 850,000 shares of the company's stock worth $5,126,000 after buying an additional 300,000 shares during the last quarter. F m Investments LLC lifted its stake in shares of Savara by 56.5% during the fourth quarter. F m Investments LLC now owns 678,813 shares of the company's stock worth $4,093,000 after buying an additional 245,100 shares during the period. Nan Fung Trinity HK Ltd. acquired a new stake in shares of Savara during the fourth quarter worth $10,182,000. Eversept Partners LP purchased a new stake in shares of Savara during the fourth quarter valued at $1,026,000. Finally, Spruce Street Capital LP purchased a new stake in shares of Savara during the fourth quarter valued at $14,539,000. Institutional investors own 87.93% of the company's stock.

Savara Trading Down 4.2%

SVRA opened at $5.51 on Friday. The stock has a market capitalization of $1.13 billion, a PE ratio of -9.84 and a beta of 0.24. Savara Inc. has a one year low of $2.43 and a one year high of $7.01. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. The business's 50 day moving average price is $5.53 and its 200 day moving average price is $5.52.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, equities research analysts expect that Savara Inc. will post -0.57 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Savara in a research note on Friday, July 17th. Oppenheimer began coverage on Savara in a research report on Friday, April 24th. They issued an "outperform" rating and a $11.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Savara from a "sell" rating to a "hold" rating in a report on Saturday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $10.14.

Savara Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.